Author(s)

Yuchen Cai, Yidan Ma, Shulei Ren, Shenyue Zhao

Corresponding Author

Shenyue Zhao

ABSTRACT

Cancer is the leading cause of death around whole world, has a high incidence rate and a high fatality rate, accounting for millions of deaths in recent years. Metastatic tumour spreads to other organs and tissues of the body and remains an incurable disease. There is an urgent need for developing one drug that can kill tumour cells with the most precise and selective targeting method. Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate (ADC) that target human trophoblast cell antigen 2 (Trop-2), which overexpresses in various type of tumour cells, such as triple-negative breast cancer (TNBC). Once Sacituzumab Govitecan’s antibody part identifies Trop-2 molecule on the cell surface, Sacituzumab Govitecan will attach the cancer cell and directly deliver anti-cancer component into cells killing the cancer cell. In both basket-designed phase I/II study and third phase clinical trial, Sacituzumab Govitecan showed promising monotherapy activity among multiple cancer cohorts, together with a satisfactory relief rate and few side effects. For example, Triple-negative breast cancer patient that has been through at least two previous treatments in a metastatic setting can receive Sacituzumab Govitecan treatment. That leads the US Food and Drug Administration to accelerate approving Sacituzumab Govitecan to treat metastatic disease cancer patients. This review gives information about the component and mechanisms of Sacituzumab Govitecan and the clinical trials and their data analysis.

KEYWORDS

Sacituzumab Govitivan (Trodelvy), Trophoblast cell antigen 2 (Trop-2), Antibody-drug conjugates (ADC), Mechanism, Clinical trials, Toxicity